CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the circulating tumour cell diagnostics company, expects revenues of at least £2.1 million in 2026, representing growth of at least 50% from last year's £1.4 million, underpinned by a commercial pipeline that has expanded 22% over the last quarter.
The AIM-listed company has emerged from a year-long restructuring sharper and leaner, having cut its cost base substantially during 2025 and recruited new leadership to drive a partnership-focused strategy centred on pharmaceutical and diagnostic companies rather than research income.
The qualifier "expected" carries weight here because CelLBxHealth's guidance is backed by contracted revenues and near-term commercial opportunities, not speculation; the pipeline momentum reflects genuine pharmaceutical and biotech engagement, the company said.
This strategic pivot is visible in recent post-closing deals announced since year-end that serve as proof of concept for the repositioning.
A master service agreement with AstraZeneca closed in May 2026, whilst AdventHealth has contracted two studies monitoring circulating tumour cells to improve cancer care; separately, The Royal Marsden NHS Foundation Trust has begun a novel clinical study in advanced non-small cell lung cancer.
The company completed its 2025 restructuring with ruthless efficiency. Headcount fell 60% to 44 employees and has since dropped further to 39 following additional cost-cutting in the first quarter of this year.
Annualised operating cash costs have been cut to £6.7 million, whilst the company consolidated into a single operating location and renegotiated supplier contracts. A sub-lease of its US facility, effective from May 2026, will reduce costs further still.
On the balance sheet, CelLBxHealth raised £8.2 million gross proceeds in a fundraise completed in December 2025 and ended the year with £7.3 million cash.
With the newly efficient operating model, that cash provides runway into the second quarter of 2027, giving the board time to execute on its commercial pipeline without immediate capital pressure.
The 2025 results show the strain of transition: operating losses widened to £19.2 million from £15.1 million, though restructuring costs of £7.7 million accounted for much of the deterioration.
Biopharma services revenue collapsed to £0.3 million from £1.6 million, reflecting the strategic shift away from research income.
